Modified stage I (T1N0M0, T2N0M0), nonsmall cell lung cancer: treatment results, recurrence patterns, and adjuvant immunotherapy.

摘要: We analyzed 96 patients who had surgery with T1N0M0 or T2N0M0 nonsmall cell lung cancer (NSCLC) to identify survival rates and recurrence patterns in well-staged evaluate adjuvant therapy. Preoperative staging included chest x-ray, gallium 67 scanning, bronchoscopy all patients. At thoracotomy, multiple mediastinal lymph node sites were routinely sampled. The results an operative mortality rate of 5.2%, the actuarial 5-year was 70.0%. Survival T1N0 (n = 44) T2N0 47) 72.1% 68.3%, respectively (p NS). not affected by type surgery, type, sex, age, race. Late death due 12 patients, a new airway malignancy three, noncancer problem six. Disease recurred 15 patients: four (9.1%) versus 11 (23.4%) p less than 0.05. Recurrence local distant 11. Second cancers developed six at mean interval 65.7 months after resection. A prospective, randomized trial systemic immunotherapy bacillus Calmette-Guerin (BCG) skin scarification carried out 29 those receiving BCG 85.9% compared 63.9% for control subjects 0.075) 69.6% study 0.077). following conclusions can be made: Resection well-staged, modified stage I NSCLC 70%. Nearly half deaths are unrelated original cancer. Recurrences more frequent but there is no difference Systemic recurrences recurrences, appreciable incidence second cancers. Adjuvant chemotherapy radiation therapy does seem justified, holds sufficient promise warrant further investigation.